Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 18, 2008, Pages 8440-8446

  Antonini, Ippolito ^a   Volpini, Rosaria ^a   Dal Ben, Diego ^a   Lambertucci, Catia ^a   Cristalli, Gloria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Antitumor activity; Benzo de isoquinolines; Cytotoxicity; DNA binding

Indexed keywords

ANTINEMATODAL AGENT; DNA; MITONAFIDE; MITONAFIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DNA BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; REACTION ANALYSIS;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; COLONIC NEOPLASMS; DNA; DRUG DESIGN; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; ISOQUINOLINES; NAPHTHALIMIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 51449093048     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.08.027     Document Type: Article

References (24)

1. Antonini I. Curr. Med. Chem. 9 (2002) U2
2. Antonini I. Curr. Med. Chem. 9 (2002) 1701
3. Antonini I. Med. Chem. Rev. Online 1 (2004) 267
4. Antonini I., Polucci P., Magnano A., Sparapani S., and Martelli S. J. Med. Chem. 47 (2004) 5244
5. Magnano A., Sparapani S., Lucciarini R., Mosca M., Amantini C., Santoni G., and Antonini I. Bioorg. Med. Chem. 12 (2004) 5941
6. Stefanska B., Bontemps-Gracz M., Antonini I., Martelli S., Arciemiuk M., Piwkowska A., Rogacka D., and Borowski E. Bioorg. Med. Chem. 13 (2005) 1969
7. Antonini I., Santoni G., Lucciarini R., Amantini C., Sparapani S., and Magnano A. J. Med. Chem. 49 (2006) 7198
8. Casado A., Rosell R., GarciaGomez R., DiazRubio E., PerezManga G., Font A., Benavides A., and Martin M. Investig. New Drugs 14 (1996) 415
9. Asbury R.F., Blessing J.A., and Soper J.T. Am. J. Clin. Oncol. Cancer Clin. Trials 17 (1994) 125
10. Borchmann P., and Schnell R. Expert Opin. Investig. Drugs 14 (2005) 1055
11. Engert A., Herbrecht R., Santoro A., Zinzani P.L., and Gorbatchevsky I. Clin. Lymphoma Myeloma 7 (2006) 152
12. Bousquet P.F., Braña M.F., Conlon D., Fitzgerald K.M., Perron D., Cocchiaro C., Miller R., Moran M., George J., and Qian X.D. Cancer Res. 55 (1995) 1176
13. Villalona-Calero M.A., Eder J.P., Toppmeyer D.L., Allen L.F., Fram R., Velagapudi R., Myers M., Amato A., Kagen-Hallet K., Razvillas B., Kufe D.W., Von Hoff D.D., and Rowinsky E.K. J. Clin. Oncol. 19 (2001) 857
14. Braña M.F., and Ramos A. Curr. Med. Chem. Anti-Cancer Agents 1 (2001) 237
15. O'Reilly S., Baker S.D., Sartorius S., Rowinsky E.K., Finizio M., Lubiniecki G.M., Grochow L.B., Gray J.E., Pieniaszek H.J., and Donehower R.C. Ann. Oncol. 9 (1998) 101
16. Nitiss J.L., Zhou J., Rose A., Hsiung Y., Gale K.C., and Osheroff N. Biochemistry 37 (1998) 3078
17. Pavlov V., Kong Thoo Lin P., and Rodilla V. Chem. Biol. Interact. 137 (2001) 15
18. Zhu H., and Ding J. Zhongguo Xinyao Zazhi 16 10 (2007) 74
19. Ramachandram B., Sankaran N.B., Karmakar R., Saha S., and Samanta A. Tetrahedron 56 (2000) 7041
20. Brana M.F., Moran M., Devega M.J.P., Pitaromero I., and Walker N. Tetrahedron 51 (1995) 9127
21. McConnaughie A.W., and Jenkins T.C. J. Med. Chem. 38 (1995) 3488
22. Morgan A.R., Lee J.S., Pulleyblank D.E., Murray N.L., and Evans D.H. Nucleic Acids Res. 7 (1979) 547
23. Baguley B.C., Denny W.A., Atwell G.J., and Cain B.F. J. Med. Chem. 24 (1981) 170
24. Antonini I., Polucci P., Cola D., Bontemps-Gracz M., Pescalli N., Menta E., and Martelli S. Anti-Cancer Drug Des. 11 (1996) 339